載入中
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
NASDAQHealthcareBiotechnology
最新資料
US$24.00
−US$0.72 · -2.91%
前收盤價
US$24.00
−US$0.72 · -2.91%
盤中時間採用ET。市場資料可能有所延遲。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日內區間
目前US$24.00
52週區間
目前US$24.00
盤中時間採用ET。市場資料可能有所延遲。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日內區間
目前US$24.00
52週區間
目前US$24.00
| 項目（USD） | 2025會計年度 |
|---|---|
| 銷貨成本 | 61.2萬 USD |
| 毛利 | −61.2萬 USD |
| 研究與開發 | 2864萬 USD |
| 銷售、一般及管理費用 | 1219.7萬 USD |
| 營業費用 | 4083.7萬 USD |
| 利息收入 | 310.6萬 USD |
| 折舊和攤銷 | 61.2萬 USD |
| 營業利益 | −4144.9萬 USD |
| 淨利 | −3986.9萬 USD |
公司資料更新於 2026年10月17日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$38.00
上漲空間 58.33%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1458.09萬0.00%2.3兆 USD0.03%US$374.07-1.15%
iShares Russell 2000 ETFIWM606.29萬0.01%789.06億 USD0.19%US$270.44-1.69%
Vanguard Extended Market ETFVXF201.18萬0.00%912億 USD0.05%US$226.57-1.80%
iShares Russell 2000 Growth ETFIWO147.78萬0.01%135.88億 USD0.24%US$338.83-2.54%
Vanguard Russell 2000 ETFVTWO139.77萬0.01%173億 USD0.06%US$109.25-1.66%
ALPS Medical Breakthroughs ETFSBIO101.19萬0.59%1.73億 USD0.50%US$50.12-4.02%
Avantis Emerging Markets Equity ETFAVEM99.44萬—272.24億 USD0.33%US$88.89-1.67%
Schwab U.S. Small-Cap ETFSCHA86.01萬0.00%212.93億 USD0.03%US$31.99-1.54%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOALPS Medical Breakthroughs ETFSBIOAvantis Emerging Markets Equity ETFAVEMSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
